| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
a Address for correspondence: Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Ismaninger Strasse 22, D-81675 München, Germany. Fax 49 89 4140 4875; e-mail Steimer{at}mail.KlinChem.med.TU-Muenchen.de
Background: Immunoassays designed for the selective measurement of cyclosporin A (CsA) inadvertently show cross-reactivity for CsA metabolites. The extent and clinical significance of the resulting overestimation is controversial. A comprehensive assessment of old and new methods in clinical specimens is needed.
Methods: In a comprehensive evaluation, CsA was analyzed in 145 samples with the new CEDIA® assay and compared with the Emit® assay with the old and new pretreatments, the TDx® monoclonal and polyclonal assays, the AxSYM®, and HPLC. All samples were from patients with liver and/or kidney transplants.
Results: The CEDIA offered the easiest handling, followed by the AxSYM, which showed the longest calibration stability. The TDx monoclonal assay provided the lowest detection limit and the lowest CVs. The mean differences compared with HPLC were as follows: Emit, 9–12%; CEDIA, 18%; AxSYM, 29%; and TDx monoclonal, 57%. The CycloTrac® RIA paralleled the Emit results. In contrast to the mean differences, substantial (>200%) and variable overestimations of the CsA concentration were observed in individual patient samples. Metabolic ratios, estimates of the overall concentrations of several cross-reacting metabolites (nonspecific TDx polyclonal/specific reference method), correlated with the apparent biases of the various monoclonal assays. Metabolic ratios varied up to 10-fold, which translated into biases for individual samples between -7% and +174%. The higher the cross-reactivity of an assay was, the higher was the range of biases observed. The interindividual differences markedly exceeded other factors of influence (organ transplanted, hepatic function).
Conclusion: Because assay bias cannot be predicted in individual samples, substantially erratic CsA dosing can result. The specificity of CsA assays for parent CsA remains a major concern. © 1999 American Association for Clinical Chemistry
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  N. Karamperis, P. Koefoed-Nielsen, A. Bagger Sorensen, C. Hojskov, J. Poulsen, and K. Jorgensen Role of metabolites and calcineurin inhibition on C2 monitoring in renal transplant patients Nephrol. Dial. Transplant., March 1, 2005; 20(3): 618 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G Morris Immunosuppressant Drug Monitoring: Is the Laboratory Meeting Clinical Expectations? Ann. Pharmacother., January 1, 2005; 39(1): 119 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Terrell, T. M. Daly, K. G. Hock, D. C. Kilgore, T. Q. Wei, S. Hernandez, D. Weibe, L. Fields, L. M. Shaw, and M. G. Scott Evaluation of a No-Pretreatment Cyclosporin A Assay on the Dade Behring Dimension RxL Clinical Chemistry Analyzer Clin. Chem., July 1, 2002; 48(7): 1059 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Streit, V. W. Armstrong, and M. Oellerich Rapid Liquid Chromatography-Tandem Mass Spectrometry Routine Method for Simultaneous Determination of Sirolimus, Everolimus, Tacrolimus, and Cyclosporin A in Whole Blood Clin. Chem., June 1, 2002; 48(6): 955 - 958. [Full Text] [PDF]
|
|
|
|
|
|
B. G. Keevil, D. P. Tierney, D. P. Cooper, and M. R. Morris Rapid Liquid Chromatography-Tandem Mass Spectrometry Method for Routine Analysis of Cyclosporin A Over an Extended Concentration Range Clin. Chem., January 1, 2002; 48(1): 69 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Holt, A. Johnston, B. D. Kahan, R. G. Morris, M. Oellerich, and L. M. Shaw New Approaches to Cyclosporine Monitoring Raise Further Concerns about Analytical Techniques Clin. Chem., June 1, 2000; 46(6): 872 - 874. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
